Low-Dose Azacitidine Plus Venetoclax Is Effective Maintenance for AML | Blood Cancers Today
Low-dose azacitidine plus venetoclax was a feasible maintenance regimen in AML after intensive or low-intensity induction therapy.
Low-dose azacitidine plus venetoclax was a feasible maintenance regimen in AML after intensive or low-intensity induction therapy.
We interview Sloane Cammock, CPNP, a nurse with LLSās Clinical Trial Support Center, about why nurses are key to patientsā wellbeing.
AbstractBackgroundQuantitative late gadolinium enhancement (LGE) cardiac magnetic resonance provides important prognostic information for sudden cardiac death (SCD) in hypertrophic cardiomyopathy (…
AbstractBackgroundCardiovascular disease (CVD) is the leading cause of death worldwide, but prevalence estimates in former professional athletes are limited.ObjectivesHUDDLE (Heart Health: Understa…
This Breakout, held at Transcatheter Interventions Online 2024, discovers the concept of sensor-guided TAVI interventions using a dedicated LV-pacing guidewire designed to deliver
The 8th Cutter Symposium focused on one of the major challenges of obtaining accurate results in nutrition studiesāthe role of hidden, so-called confounding factors in…
The fellows discussed how to choose a career path, what makes a good mentor, and more.
The event was hosted by James Spratt, St Georgeās University Hospital NHS Trust, London, UK with and Emanuele Barbato Sant Andrea Hospital, Rome, IT in…
A new study recorded data on the type of treatment received in each line of therapy for advanced urothelial carcinoma, as well as the attrition…
Patients who received Orca-T had āsuperiorā all-grade chronic GVHD-free survival after allogeneic HSCT compared with those recieved PTCy.